Hyperacute outer retinal dysfunction can affect children following a fever, and may include symptoms of bilateral vision loss and disruption of external limiting membrane.

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

A multicenter study led by researchers from the State Key Laboratory of Ophthalmology in China has characterized a distinct ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

CXL does not alter topographic or refractive parameters, allowing clinicians to fit these patients with scleral lenses before the procedure.

Sociodemographic factors may affect visual acuity outcomes following unilateral pediatric cataract extraction.

Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)NEW YORK, Feb. 18, 2025 ...

COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMDCompany confirms topline results for ...

At a mean of 16.1 days after fever onset, patients experienced initial symptoms including sudden vision loss, visual field ...

The first of Opthea’s (ASX:OPT) two phase III eye disease trials has hit a key development milestone, with the last patient ...

At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid ...

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...